Dr Mohammed AlHilali
MB BCh, MRCP (UK), FRCR
Languages spoken
English, Arabic
Expert in
Gastrointestinal and hepatopancreatobiliary cancers; neuroendocrine tumours and rare cancers; stereotactic ablative radiotherapy (SABR) for abdominal tumours.
Overview
Dr Mohammed AlHilali is a Consultant Clinical Oncologist at the Northern Centre for Cancer Care in Newcastle upon Tyne. He is a Unity Specialist Advisor at GenesisCare Leeds, contributing to the MR-Linac service. His specialist practice covers gastrointestinal and hepatopancreatobiliary cancers, neuroendocrine tumours and rare malignancies. He combines anti-cancer drug treatments with radiotherapy, with a particular interest in stereotactic ablative radiotherapy (SABR) for abdominal tumours and peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumours.
He graduated in medicine from Ain Shams University, Cairo, in 2007, completed MRCP (UK) in 2016 and gained his FRCR in Clinical Oncology in 2021. Following core medical training in South Yorkshire, he completed higher specialist training in Clinical Oncology in the North East of England. He was awarded his Certificate of Completion of Training (CCT) and joined the GMC Specialist Register in 2023 and was appointed as a consultant in October of the same year.
Dr AlHilali is the NET Oncology Lead at Newcastle Hospitals, Training Programme Director for Clinical Oncology in the North East, and a Lecturer in Cancer Education at Newcastle University. He contributes to regional multidisciplinary cancer services and research into treatment outcomes, PRRT and breathing-motion management during radiotherapy. He also creates accessible cancer information for patients and families at dralhilali.com.
A cancer diagnosis can bring uncertainty and difficult decisions. My role is to help you understand your options, listen to what matters most to you, and guide you through your care with honesty, compassion and respect.
- Dr AlHilali
Book an appointment
I’m available for private consultations. If you have any concerns, don't hesitate to get in touch.
Gastrointestinal cancers, including oesophageal, stomach, pancreatic, liver, and bile duct cancers; neuroendocrine tumours and selected rare malignancies.
Precision radiotherapy and abdominal stereotactic ablative radiotherapy (SABR); respiratory-motion assessment and management; image-guided and adaptive radiotherapy; integration of radiotherapy with systemic anti-cancer treatment.
Real-world outcomes research in pancreatic and oesophageal cancer and neuroendocrine tumours; multidisciplinary service development; undergraduate and postgraduate cancer education.
- Fellow of the Royal College of Radiologists (FRCR); Member of the Royal Colleges of Physicians of the United Kingdom (MRCP (UK))
Teaching Innovation Prize, Yorkshire and the Humber Core Medical Training Conference, 2018, for the Chesterfield CMT Teaching Programme (programme founder).
- AlHilali M, et al. P1.125. Challenging a Histology-Led Paradigm: Comparable Real-World Survival After Definitive Non-Surgical Treatment in Oesophageal Adenocarcinoma and Squamous Cell Carcinoma. Diseases of the Esophagus. 2026;39(Supplement 1):doag077.273. https://doi.org/10.1093/dote/doag077.273. Published conference abstract.
- AlHilali M, et al. Real-world survival outcomes following lutetium-177 dotatate PRRT in gastroenteropancreatic neuroendocrine tumours: a 138-patient UK experience. Endocrine Abstracts. 2025;114:P15. https://www.endocrine-abstracts.org/ea/0114/ea0114P15. Published poster abstract.
- Al-Baho A, et al. Clinical audits in a postgraduate general practice training program: an evaluation of 8 years experience. PLoS One. 2012;7(9):e43895. https://pubmed.ncbi.nlm.nih.gov/22970146/.
- Affiliations: Newcastle upon Tyne Hospitals NHS Foundation Trust; Newcastle University; NHS England North East and North Cumbria; Northern Radiotherapy Network. GenesisCare Leeds Unity Specialist Advisor.